Ocular neovascularization is the most common cause of blindness in all age groups: retinopathy of prematurity in children, diabetic retinopathy in working-age adults and age-related macular degeneration in the elderly. In principle, destructive angiogenesis in the eye can be ameliorated by either direct inhibition of neovascularization or by controlling vessel loss in order to reduce the hypoxic stimulus that drives neovascularization. Retinopathy is modeled in the mouse eye with oxygen-induced vessel loss, which precipitates hypoxia-induced retinopathy, allowing for assessment of retinal vessel loss, vessel regrowth after injury and pathological angiogenesis 1 .
The role of lipids in angiogenesis is just beginning to be defined 3, 4 . The major polyunsaturated fatty acids (PUFA) found in the retina are docosahexaenoic acid (DHA; C22:6o-3) and arachidonic acid (C20:4o-6), both found primarily in neural and vascular cell membrane phospholipids 5 . Eicosapentaenoic acid (EPA; C20:5o-3), the precursor to DHA, is found in the retinal vascular endothelium 6 . Dietary sources of o-3-PUFA and o-6-PUFA, as well as PUFA released as free fatty acids by phospholipase A 2, contribute to a pool of substrates 7 . These can then be converted to bioactive intermediaries such as eicosanoids from arachidonic acid, neuroprotectins from DHA, D series resolvins from DHA and E series resolvins from EPA 8, 9 . Emerging knowledge of lipid mediators 3, 6 and epidemiologic data linking PUFA and neovascular age-related macular degeneration indicate that EPA, DHA and arachidonic acid may function in vivo to regulate retinal vaso-obliteration and neovascularization 3 . We therefore tested whether moderate dietary intake of o-3-PUFA or o-6-PUFA can alter retinal angiogenesis. We also tested the role of PUFA using a genetic model in which overexpression of the C. elegans fat-1 gene in transgenic mice converts o-6-PUFA to o-3-PUFA, resulting in elevated tissue levels of o-3-PUFA 10 .
We subjected mice on a completely defined isocaloric diet enriched with 2% of total fatty acids from either o-3-PUFA (DHA and EPA) or o-6-PUFA (arachidonic acid) (Supplementary Table 1 online), modeled after a Japanese or Western diet, respectively, to oxygen-induced retinopathy 1 . We also examined retinopathy in the Fat-1 mouse on an o-6-PUFA diet (Supplementary Table 2 online).
Lipid content of milk reflects the lipid profile of the mother's diet 9, 11 . We found that retinal lipid composition in the pups reflected the pups' (and the mother's) dietary intake of lipids. In the retinas of the milk-fed pups at postnatal day (P) 17, the levels of all of the principal o-3-PUFA (including EPA, docosapentaenoic acid (DPA)-o-3 and DHA) were increased with either the o-3-PUFA-enriched diet or with the expression of the fat-1 gene (P r 0.005). There was also less retinal o-6-PUFA (including arachidonic acid, docosatetraenoic acid (DTA) and DPA-o-6) in the o-3-PUFA group relative to the o-6-PUFA group, and there was less in Fat-1 mice relative to wildtype mice (P r 0.005). Enriching o-3-PUFA through diet or through expression of fat-1 resulted in a 450% decrease in the total o-6/o-3-PUFA ratio ( Table 1) .
We found that a lower retinal o-6/o-3-PUFA ratio had a protective effect against pathological angiogenesis. At P17, mice on the o-6-PUFA versus the o-3-PUFA diet had a vaso-obliterated/total retinal area of 21.5 ± 0.4% versus 13.7 ± 0.5%, P r 0.0001 (Fig. 1a,b) . Moreover, P17 pups fed an o-3-PUFA versus an o-6-PUFA diet were significantly protected from pathologic neovascularization (5.7 ± 0.4% versus 9.0 ± 0.6% neovascularization, P r 0.0001 (Fig. 1a,c) .
We confirmed in Fat-1 mice 10 that increased retinal o-3-PUFA levels ( Table 1 ) inhibited neovascularization. At P17, after oxygeninduced retinopathy 1 wild-type mice lacking the fat-1 transgene had more extensive vaso-obliteration (21.9 ± 0.7% versus 11.9 ± 0.5%) of total retinal area (P r 0.001) (Fig. 1d,e ) and more severe retinal neovascularization (8.3 ± 0.8% versus 4.3 ± 0.7%) of total retinal area (P r 0.001) (Fig. 1d,f) than Fat-1 homozygotes that had a decreased o-6/o-3-PUFA ratio ( Table 1) .
The o-3-PUFA-induced protection against retinopathy at P17 was due to increased regrowth of vessels and not to decreased oxygeninduced vessel loss during hyperoxia. No difference in vessel loss was observed following 24 h of 75% oxygen exposure between the different experimental groups (data not shown). After 5 d exposure to 75% oxygen, retinas from mice (P12) on a o-3-PUFA or o-6-PUFA diet, and from Fat-1 mice or controls, showed no difference in vaso-obliteration (Fig. 1g,h) . However, the o-3-PUFA-fed mice showed less avascular retinal area than did o-6-PUFA-fed mice starting between P12 and P13. This reduction was maintained through P17 (Fig. 1g) . Similar results were obtained in Fat-1 transgenic mice and controls (Fig. 1h) . Table 1 Fatty acyl composition (%) of retinas from P17 pups Resolvins (resolution phase interaction products) and neuroprotectins are o-3-PUFA bioactive products derived from EPA and DHA, respectively (Fig. 2a) . They were first identified in resolving inflammatory exudates in DHA-enriched tissues 12 . Their contribution to the regulation of angiogenesis has not been investigated 12 .
Neither resolvins nor neuroprotectins were detected by liquid chromatography followed by tandem mass spectroscopy (MS-MS) in the o-6-PUFA-diet retinas. However, in the o-3-PUFA-diet retinas, we identified o-22-hydroxy-protectinD1 (PD1) and resolvinE2 (RvE2), which are markers of the biosynthesis of neuroprotectinD1 (NPD1) and resolvinE1 (RvE1), respectively (Fig. 2b,c , Supplementary Table 3 online) 13, 14 .
In mice without o-3-PUFA diet supplementation, a very low intraperitoneal (i.p.) dose of resolvinD1 (RvD1), RvE1 or NPD1 (10 ng/d, an amount comparable to the total found in the retinas of mice on the o-3-PUFA diet, Supplementary Table 3) conferred significant protection from vaso-obliteration (P r 0.0001) (Fig. 2d ) and neovascularization (P r 0.03) (Fig. 2e) at P17 compared with the control.
We saw no difference in normal vascular development at P6 between o-3-and o-6-PUFA-fed mice nor between controls and RvD1, RvE1 or NPD1-treated (P4-P5) mice ( Supplementary Fig. 1 online). No differences in vessel loss were observed between controls and mice treated from P5-P8 with either NPD1, RvD1or RvE1 (Fig. 2f) . At P17 there was considerably less vaso-obliteration in all treatment groups compared with controls ( Fig. 2d) , indicating that these compounds also confer their protective actions against retinopathy by means of enhanced vessel regrowth, not protection from vessel loss. These findings coincide with our dietary PUFA results and demonstrate that the protective effect of o-3-PUFAs against retinal neovascularization is mediated in part through the potent bioactive mediators RvD1, RvE1 and NPD1.
We next addressed the mechanism by which RvD1, RvE1 and NPD1 might mediate the o-3-PUFA protection against retinal neovascularization. RvE1 can block the production of proinflammatory cytokines when it binds to the receptor ChemR23 (refs. 15,16) . In retinal whole-mounts we localized ChemR23 to a subset of colonystimulating factor-1-receptor-positive (Csf1r + ) microglia that were morphologically distinct from resident microglia. These cells were closely associated with retinal blood vessels (Fig. 2g) . ChemR23 was not detected elsewhere in the retina under these conditions. These findings are consistent with the idea that o-3-PUFA-derived biomediators interact with receptors on microglial cells to decrease proinflammatory cytokine production.
We next examined the role of the inflammatory cytokine tumor necrosis factor (TNF)-a. Modulation of TNF-a production influences vascular growth in other systems through endothelial cell cycle regulation 17, 18 . Moreover, mice lacking TNF-a have less oxygeninduced retinopathy 19 . Therefore, we hypothesized that o-3-and o-6-PUFAs and their bioactive metabolites act in part through the regulation of TNF-a expression.
Consistent with our hypothesis, we found that an o-3-PUFA diet potently suppressed retinal expression of Tnf mRNA, encoding TNF-a, by B90% (P r 0.0001) during hyperoxia (P8) and hypoxia (P14) compared with expression in mice on an o-6-PUFA diet (Fig. 3a) . Retinal TNF-a protein levels were also suppressed by B30% (P r 0.001) compared with those in mice on an o-6-PUFA diet (Fig. 3a) . Suppression of TNF-a in the o-6-PUFA diet group through i.p. injection of a TNF-a receptor fusion protein (etanercept), which sequesters TNF-a, resulted in a reduction in avascular area at P17 (P r 0.001) (Fig. 3b) , as well as a reduction in pathologic neovascularization (P r 0.05) (Fig. 3c) , to levels seen in o-3-PUFA fed mice. Mice on an o-3-PUFA diet with suppressed but not ablated levels of TNF-a (Fig. 3b) had further suppression of both vasoobliteration (P r 0.001) and neovascularization (P r 0.02) with i.p. etanercept treatment (Fig. 3b,c) . Similar results were observed with intraocular injections of etanercept ( Supplementary Fig. 2  online) . These data indicate that partial reduction of TNF-a levels with an o-3-PUFA diet seems to be sufficient to help mediate a protective effect against retinopathy.
The complete loss of TNF-a had a more significant effect on retinal neovascularization and vessel loss compared with the partial suppression with etanercept. As expected, Tnf +/+ wild type mice fed an o-3-PUFA diet were protected from vaso-obliteration and neovascularization compared with their o-6-PUFA-fed counterparts (P r 0.00001) (Fig. 3d,e) . However, in Tnf -/-mice at P17 there was a much larger but equal reduction in both diet groups in both vasoobliteration and neovascularization. Under the condition of complete loss of TNF-a there was no further protection against retinopathy (vaso-obliteration or neovascularization) in o-3-PUFA fed mice and no increase in retinopathy in o-6-PUFA fed mice (Fig. 3d,e) indicating that TNF-a has a crucial role in the disease process. We then sought the cellular source of TNF-a in the retina. Although several cell types can produce TNF-a, monocyte-derived cells are a major source 20 . Microglia, macrophages and dendritic cells are Csf1r + inflammatory cells that are critical to the development and repair of the retinal vasculature 21, 22 . To determine whether these cells or vascular endothelial cells produce TNF-a in retinopathy, we immunohistochemically labeled and localized TNF-a, Csf1r and vascular endothelial cells with confocal microscopy in retinal whole-mounts from mice on an o-6-PUFA diet (Fig. 3f) . TNF-a was found only in the subset of Csf1r + cells that were associated with the retinal vasculature. This implies that under these experimental conditions, the primary source of TNF-a is a subpopulation of Csf1r + macrophages or microglial cells that are in close proximity to blood vessels.
Monocyte or macrophage induction of Tnf gene expression is predominately dependent upon an upstream promoter region containing NF-kB DNA-binding motifs 23 . Using NF-kB-luciferase (NF-kB-Luc) reporter mice 24 , we found that NF-kB activity was increased B100% (P r 0.00001) in the retinas of o-6-PUFA versus o-3-PUFA-fed mice (Fig. 3g) . In retinal whole-mounts, NF-kB transcriptional activity was found in a subset of microglia closely associated with the retinal vasculature (Fig. 3h) , as were ChemR23 (Fig. 2g) and TNF-a (Fig. 3f) . These results indicate that a subset of retinal macrophages or microglia may be involved in retinal angiogenesis, acting in part through the regulation of NF-kB-driven TNF-a production.
DHA and EPA acted on Csf1r + microglia or macrophages in culture to inhibit Tnf mRNA production ( Supplementary Fig. 3 online) . Furthermore, the metabolites NPD1, RvD1 and RvE1 dosedependently reduce Tnf mRNA expression in macrophages in culture and in other inflammatory models 15, [25] [26] [27] .
In summary, o-3-and o-6-PUFAs significantly influence vascular growth and pathology. EPA, DHA and their potent bioactive products (NPD1, RvD1 and RvE1) at physiological levels reduce pathologic neovascularization through enhanced vessel regrowth after vascular loss and injury. Macrophages or microglia are a critical component of retinal vascular growth and repair 21, 22 . In the retina, increased dietary o-6-PUFA (arachidonic acid) increases activated microglial production of TNF-a, which is suppressed with elevated o-3-PUFA levels (DHA, EPA). These effects on angiogenesis are likely to be important for retinopathy as well as other pathologies where vascular loss precipitates disease. The o-3-PUFA suppressive effect on retinopathy in the mouse eye is comparable in magnitude to that of treatment with a vascular endothelial growth factor (VEGF) inhibitor 28 and it is likely to be additive to anti-VEGF therapy, as VEGF was not significantly suppressed with the o-3-PUFA diet (data not shown).
These results indicate that enriching the sources of o-3-PUFA may be an effective therapeutic approach to help prevent proliferative retinopathy. The resolvins RvD1 and RvE1 and the neuroprotectin NPD1 are potent anti-inflammatory and pro-resolving mediators 29 . The present study establishes the first results to our knowledge indicating that these recently discovered mediators are also potent regulators of angiogenesis. If supplementation with DHA, EPA or their bioactive mediators is found to be as effective in ameliorating retinal vascular disease in humans as was the case in mice in the present study, this cost-effective intervention could benefit millions of people.
METHODS
Mice. These studies adhered to the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by Children's Hospital Animal Care and Use Committee. For diet studies, C57BL/6 mothers at delivery were fed a defined rodent diet with 10% (w/w) safflower oil containing either 2% o-6-PUFAs (arachidonic acid) and no o-3-PUFAs (DHA and EPA), or 2% o-3-PUFAs and no o-6-PUFAs (Supplementary Table 1) . Lipids in the diet were stable over time with respect to oxygen exposure, as there was no detectable lipid oxidation nor lipid decomposition over the course of the experiments nor with cold storage of feed for a year (Supplementary Table 4 online). Dietary PUFAs were produced by DSM Nutritional Products under the trade name ROPUFA. The arachidonic acid and DHA supplements, under the trade names ARASCO and DHASCO respectively, were obtained from Martek Biosciences Corporation. The feed was produced at Research Diets Incorporated. Fat-1 transgenic mice contain a humanized fat-1 cDNA driven by the cytomegalovirus enhancer and a chicken b-actin promoter 10 . Fat-1 and control dams were fed a defined diet with elevated o-6-PUFAs (Supplementary Table 2 ). TNF-a-deficient (Tnf -/-, Jackson Laboratories stock no. 003008) and Tnf +/+ wild type (stock no. 101045) mice were administered the same diets as the C57BL/6 mice above. The NF-kBLuc reporter mice (stock no. 006100) were made using the pBIIX-luciferase targeting construct with two copies of the NF-kB binding sites from the immunoglobulin k light chain intronic enhancer in front of a minimal Fos promoter as described previously 24 .
O 2 -induced retinopathy (vessel degeneration, regrowth and pathological neovascularization). To induce vessel loss, mice were exposed to 75% oxygen from P7 to P12 (ref. 1). Retinal vessel loss was assessed at P12 and vessel regrowth at P13, P15 and P17. Retinal neovascularization was evaluated at P17, 5 d after return to room air, when the neovascular response is greatest.
Quantification of vaso-obliteration and retinal neovascularization. See Supplementary Methods online.
Resolvins and neuroprotectins. Lipid mediator profiles were analyzed from the retinas of P17 pups fed either o-3-or o-6-PUFA enriched diets and exposed to oxygen from P7-P12. PUFA-derived products were extracted, identified and quantified using a deuterium-labeled internal standard and MS-MS based mediator informatics program. Results were obtained from retinas of six mice, each from a separate litter. See Supplementary Methods for further details.
Lipid extraction and fatty acid analysis. Retinal samples containing one retina each were analyzed and results were averaged to derive a mean score. Extracted methyl esters were quantified on a model 6890 series gas chromatograph (Agilent Technologies) using a fast gas chromatography method using a 1-ml injection at a 25:1 split ratio. See Supplementary Methods for further details.
TNF-a receptor (etanercept) treatment. Intraperitoneal injections of a soluble TNF-a receptor (etanercept, 500 mg per mouse) were given at P7, P12, P14 and P16 to mice raised on an o-3-or o-6-PUFA-rich diet as previously described 30 . Retinas were isolated, fixed, stained and whole-mounted at P17 to evaluate vaso-obliteration and retinal neovascularization, as previously described 1, 21 .
Immunohistochemistry. Eyes were enucleated from mice fed an elevated o-6-PUFA diet. Following a 1-h fixation in 4% paraformaldehyde at 25 1C, the retinas were dissected, permeabilized overnight at 4 1C with 1% Triton X-100 (T-8787, Sigma) in PBS, and stained with isolectin B4, as described in Supplementary Methods. Retinal microglia were visualized in retinas from mice with green fluorescent protein expression under the control of Csf1r regulatory elements (Jackson Laboratories stock no. 005070). Fluorescence was enhanced with a fluorescein isothiocyanate (FITC)-labeled secondary antibody to green fluorescent protein (F6005, Sigma). Antibodies to TNF-a (ab39542,
